In June 2012, Compugen and Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, jointly established Neviah Genomics, a start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Neviah Genomics operates from the Israel Bioincubator of MS Ventures, the strategic corporate venture capital arm of Merck Serono, in Yavne, Israel.
In January 2015, Neviah Genomics announced that it had discovered and experimentally validated a set of biomarkers for the early detection of chronic drug-induced liver toxicity. Based on these results, the company is further developing its PropheTox™ Bioassay, targeting 2016 for its commercial introduction.
“Neviah Genomics is a perfect illustration of our goals behind the establishment of the Israel Biotech Incubator: to leverage Israeli science and know-how and get access to novel products and technologies for the benefit of Merck Serono’s core therapeutic areas. In this regard, we are delighted to collaborate with Compugen, one of the premier biotech companies in Israel and a world leading predictive drug discovery company. We believe that our joint technology and resources represent a unique basis for a start-up to enter this emerging field that has the potential to significantly reduce the risk of drug discovery and development.”
Susan Herbert, Executive Vice President, Global Business Development and Alliance Management at Merck Serono.